Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma
10.3760/cma.j.issn.0253-2727.2018.07.008
- VernacularTitle: 自体造血干细胞移植治疗进展/复发鼻型结外NK/T细胞淋巴瘤16例临床分析
- Author:
Fangfang YUAN
1
;
Qingsong YIN
;
Yuewen FU
;
Qian WANG
;
Lin CHEN
;
Ruihua MI
;
Yufu LI
;
Xudong WEI
;
Yongping SONG
Author Information
1. Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
- Publication Type:Journal Article
- Keywords:
Lymphoma, extranodal NK-T-cell;
Autologous hematopoietic stem cell transplantation;
Antineoplastic combined chemotherapy protocols;
Treatment outcome
- From:
Chinese Journal of Hematology
2018;39(7):569-572
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy and safety of asparaginase based chemotherapy bridging autologous hematopoietic stem cell transplantation (auto-HSCT) in the treatment of 16 patients with nasal type extranodal NK/T-cell lymphoma (ENKTL).
Methods:From January 2012 to June 2017, 16 patients with nasal type extranodal NK/T-cell lymphoma reached complete remission by L-asparaginase based regimens, and then received auto-HSCT.
Results:①Of the 16 patients, 12 were males and 4 females, with a median age of 35.5 (14-61) years. There were 11 patients in the first complete remission (CR1) and 5 in the second CR (CR2) before transplantation, respectively. EB virus (EBV) DNA (EBV-DNA) was negative and positive in 13 and 3 cases respectively before transplantation. ②Hematopoietic reconstitution was achieved in all 16 cases. The median time for neutrophils implantation was 12 (8-17) days, and that of platelet implantation was 15.5 (12-24) days. ③To the last follow-up, there were no transplant related deaths, 3 patients died of disease progression. The median overall survival (OS) time and progression-free survival time (PFS) were not reached. Seven patients lived with no disease progression more than 2 years. ④The OS and PFS of patients at CR1 before auto-HSCT are better than that of patients at CR2, but there was no statistically significant difference (P=0.162, P=0.123). There was no significant difference in OS and PFS between EBV-DNA negative and positive patients before transplantation (P=0.280, P=0.244).
Conclusions:L-asparaginase based regimens bridging auto-HSCT is a safe and highly effective for advanced-stage and relapsed ENKTL treatment.
